B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KCNA5

MOLECULAR TARGET

potassium voltage-gated channel subfamily A member 5

UniProt: P22460NCBI Gene: 37417 compounds

KCNA5 (potassium voltage-gated channel subfamily A member 5) is targeted by 7 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KCNA5

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1nifedipine5.34208
2acacetin3.9953
3oroidin2.7715
44 methoxyflavone2.7114
5Quinidine1.102
6Bupivacaine0.691
7Flecainide0.691

About KCNA5 as a Drug Target

KCNA5 (potassium voltage-gated channel subfamily A member 5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 7 compounds with documented KCNA5 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KCNA5 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.